<DOC>
	<DOCNO>NCT00780455</DOCNO>
	<brief_summary>Studying effectiveness functional rehabilitation protocol ( FRP ) early Relapsing Remitting Multiple Sclerosis ( RRMS ) patient treat Betaferon compare physical ability patient without FRP .</brief_summary>
	<brief_title>Rehabilitation Study MS Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Female Male patient age 18 ; Confirmed diagnosis RRMS accord MacDonald Poser criterion ; First indication Betaferon treatment ( described Summary Product Characteristics ( SmPC ) ) ; No relapse multiple sclerosis ( MS ) last two month inclusion ; Walking patient Expanded Disability Status Scale ( EDSS ) score &gt; 1 &lt; /= 4 inclusion visit ; Female childbearing potential must agree practice adequate contraception method duration study ; Patient follow study comply procedures trial protocol Laboratory evaluation ( i.e . evaluation hepatic enzyme gammaGT , full blood count differential white blood cell [ WBC ] ) must available result must normal ; Written inform consent . Any contraindication Betaferon describe SmPC product ; Patient previously orthopaedic surgical intervention within past year inclusion ; Patient previously include study ; Patient previously treat within past 3 month Rebif , Avonex Copaxone ; Patient previously treat within past 12 month Betaferon ; Participation clinical trial within past 30 day involve investigational drug intake .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>KineSEP</keyword>
	<keyword>Rehabilitation</keyword>
	<keyword>Betaferon</keyword>
</DOC>